We claim:

1. A compound of Formula I or pharmaceutically acceptable salt, ester or solvate thereof,



Formula I

wherein

Q is  ; R_0 is selected from carbonyl or methylene;

X_b is a chelating agent or  ; X_c is a chelating agent or  ; X_d is a chelating agent or  ; X_e is a chelating agent or  ; X_f is a chelating agent or  ; X_g is a chelating agent or  ; X_a is a chelating agent;

R_{a1}, R_{b1}, R_{c1}, R_{d1}, R_{e1}, R_{f1} and R_{g1} are all R_{y1};

R_{a2}, R_{b2}, R_{c2}, R_{d2}, R_{e2}, R_{f2} and R_{g2} are all R_{y2};

R_{a3}, R_{b3}, R_{c3}, R_{d3}, R_{e3}, R_{f3} and R_{g3} are all R_{y3};

R_{y1}, R_{y2} and R_{y3} are each independently selected from hydrogen, deuterium, tritium, R_Y, hydroxyl, mercapto, nitro, cyano, oxo, thio, halogen, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$ or $-C(=S)R_k$;

or, R_{y2} is connected to R_{y1} (or R_{y3}) to form $R_{ring\ A}$;

R_Y is selected from a C1-C16 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl (including a fused aryl, and the like), or a 5-14 membered heteroaryl (including a fused heteroaryl); and $R_{ring\ A}$ is a 3-12 membered heterocyclic alkyl or a 5-14 membered heteroaryl;

R_Y and $R_{ring\ A}$ are optionally substituted with one or more substituents P_1 or unsubstituted;

the substituent P_1 selected from deuterium, tritium, hydroxyl, mercapto, nitro, cyano, oxo, thio, halogen, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$, $-C(=S)R_k$ or R_W; wherein R_W is selected from a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted;

the substituent P_2 selected from deuterium, tritium, hydroxyl, mercapto, nitro, cyano, oxo, thio, halogen, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$, $-C(=S)R_k$ or R_X; wherein R_X is selected from a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; and R_X is optionally substituted with one or more substituents P_3 or unsubstituted;

the substituent P_3 selected from deuterium, tritium, hydroxyl, mercapto, nitro, cyano, oxo, thio, halogen, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$, $-C(=S)R_k$ or R_V; wherein R_V is selected from a C1-C6 alkyl, a C1-C6

alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; and R_V is optionally substituted with one or more substituents P_4 or unsubstituted;

the substituent P_4 is selected from deuterium, tritium, halogen, hydroxyl, mercapto, nitro, cyano, oxo, thio, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$, $-C(=S)R_k$, a C1-C6 alkyl, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, a halogenated C1-C6 alkyl, an amino-substituted C1-C6 alkyl, a carboxyl-substituted C1-C6 alkyl, a sulfo-substituted C1-C6 alkyl, a C1-C6 alkoxy, an amino-substituted C1-C6 alkoxy, a carboxyl-substituted C1-C6 alkoxy, a sulfo-substituted C1-C6 alkoxy, a C1-C6 alkyl thioether group, an amino-substituted C1-C6 alkyl thioether group, a carboxyl-substituted C1-C6 alkyl thioether group, a sulfo-substituted C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl;

R_k is selected from hydrogen, deuterium, tritium, halogen, $-NR_iR_j$, a C1-C6 alkyl, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, a halogenated C1-C6 alkyl, an amino-substituted C1-C6 alkyl, a carboxyl-substituted C1-C6 alkyl, or a sulfo-substituted C1-C6 alkyl;

R_1, R_2, R_3, R_i and R_j are each independently selected from hydrogen, deuterium, tritium, hydroxyl, mercapto, nitro, cyano, halogen, $-S(=O)R_z$, $-S(=O)OR_z$, $-S(=O)(=O)R_z$, $-S(=O)(=O)OR_z$, a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, a halogenated C1-C6 alkyl, an amino-substituted C1-C6 alkyl, a carboxyl-substituted C1-C6 alkyl, or a sulfo-substituted C1-C6 alkyl;

R_z is selected from hydrogen, deuterium, tritium, halogen, a C1-C6 alkyl, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, or a halogenated C1-C6 alkyl;

a, b, c, d, e, f and g are each independently selected from integers between 0 and 6;

L_1 is selected from a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; wherein the 3-12 membered

cycloalkyl, the 3-12 membered heterocyclic alkyl, the 5-14 membered aryl, or the 5-14 membered heteroaryl is optionally substituted with one or more substituents P_1 or unsubstituted;

L_2 is selected from $-L_3-$ or $-NH-(CH_2)_t-L_3-$; L_3 is selected from a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; wherein the 3-12 membered cycloalkyl, the 3-12 membered heterocyclic alkyl, the 5-14 membered aryl, or the 5-14 membered heteroaryl is optionally substituted with one or more substituents P_1 or unsubstituted;

the heteroatom of the 3-12 membered heterocyclic alkyl or the 5-14 membered heteroaryl is selected from one or more of N, O and S, and the 3-12 membered heterocyclic alkyl or the 5-14 membered heteroaryl has 1, 2, or 3 heteroatoms;

m, n and t are each independently selected from integers between 0 and 6.

2. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein the compound of Formula I is:



Formula Ia

wherein X_b is a chelating agent; R_{a1} and R_{a3} are each independently selected from hydrogen, deuterium, tritium, R_Y; R_Y is selected from a C1-C6 alkyl, a deuterated C1-C6 alkyl or a tritiated C1-C6 alkyl; and R_{a2} is selected from hydrogen, deuterium, or tritium; or, R_{a2} is connected to R_{a1} (or R_{a3}) to form $R_{\text{ring A}}$, the $R_{\text{ring A}}$ is a tetrahydropyrrole ring; and a is 0, 1 or 2.

3. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 2, wherein the compound of Formula Ia is selected from:



VWT011400,



VWT011600,



VWT019000,



VWT019300,



VWT020100,



VWT021400,



VWT021700 ,



VWT022100 ,



VWT023800 ,



VWT032100 ,



VWT032200 ,



VWT044400 ,



VWT044600 ,



VWT044800 ,



VWT044900 .

4. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein the compound of Formula I is:



Formula Ib

wherein X_b is a chelating agent; R_{a1} and R_{a3} are each independently selected from hydrogen, deuterium, tritium or R_Y; R_Y is selected from a C1-C6 alkyl, a deuterated C1-C6 alkyl or a tritiated C1-C6 alkyl; R_{a2} is a C1-C14 alkyl that is optionally substituted with one or more substituents P_1; and the substituent P_1 is selected from deuterium, tritium, carboxyl, sulfo-group, or R_W; wherein R_W is selected from a C1-C6 alkoxy; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; and the substituent P_2 is selected from -C(=O)OR_k or R_X; wherein R_X is selected from a C1-C6 alkoxy or a C1-C6 alkyl thioether group; R_X is optionally substituted with one or more substituents P_3 or unsubstituted; and the substituent P_3 is selected from -C(=O)OR_k; R_k is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl; and a is 0, 1 or 2.

5. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 4, wherein the compound of Formula Ib is selected from:



,


,


,


.

6. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein X_b is a chelating agent; R_{y1} is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, or a deuterated C1-C6 alkyl; R_{y3} is R_Y; R_Y is selected from a C1-C6 alkyl; R_Y is optionally substituted with one or more substituents P_1; and R_{y2} (R_{a2}) is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, or a deuterated C1-C6 alkyl; or, R_{y2} is connected to R_{y1} (or R_{y3}) to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a is 0, 1 or 2.

7. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 6, wherein the compound of Formula I is:



Formula Ic

wherein X_b is a chelating agent;

R_{a1} is selected from hydrogen, deuterium, tritium, or a C1-C6 alkyl;

R_{a3} is R_Y; wherein R_Y is selected from a C1-C6 alkyl; and R_Y is optionally substituted with one or more substituents P_1; the substituent P_1 is selected from deuterium, tritium, -S(=O)R_k, -S(=O)OR_k, -S(=O)(=O)R_k, -S(=O)(=O)OR_k or R_W; wherein R_W is selected from oxadiazolyl, phenyl or benzopyrrolyl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; the substituent P_2 is selected from deuterium, tritium, hydroxyl, mercapto, cyano, oxo, thio, halogen or R_X; wherein R_X is a C1-C6 alkyl; R_k is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl;

R_{a2} is selected from hydrogen, deuterium, tritium; or, R_{a2} is connected to R_{a1} (or R_{a3}) to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a is 0, 1 or 2.

8. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 7, wherein the compound of Formula Ic is selected from:



VWT022600 ,


VWT032000 ,


VWT032900 ,


VWT033000 ,


VWT035700 ,


VWT044700 .

9. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 6, wherein the compound of Formula I is:



Formula Id

wherein X_b is a chelating agent;

R_{a1} is selected from hydrogen, deuterium, tritium, or a C1-C6 alkyl;

R_{a3} is R_Y; wherein R_Y is selected from a C1-C6 alkyl; and R_Y is optionally substituted with one or more substituents P_1; the substituent P_1 is selected from $-C(=O)R_k$, $-C(=O)OR_k$; R_k is selected from hydrogen, deuterium, tritium, $-NR_iR_j$, a C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl; R_i and R_j are each independently selected from hydrogen, deuterium, tritium, hydroxyl, mercapto, cyano, $-S(=O)R_z$, $-S(=O)OR_z$, $-S(=O)(=O)R_z$ or $-S(=O)(=O)OR_z$; wherein R_z is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl;

R_{a2} is selected from hydrogen, deuterium, tritium, or a deuterated C1-C6 alkyl; or, R_{a2} is connected to R_{a1} (or R_{a3}) to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a is 0, 1 or 2.

10. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 9, wherein the compound of Formula Id is selected from:



VWT024000 ,



VWT031600 ,



VWT032600 ,



VWT032700 ,



VWT032800 ,



VWT024100 ,



VWT031700 ,



VWT031800 ,



VWT032300 ,



VWT035400 .

11. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 6, wherein the compound of Formula I is:



Formula Iz

wherein,

X_b is a chelating agent;

R_{a1} is selected from hydrogen, deuterium, tritium, or a C1-C6 alkyl;

R_{a3} is R_Y; wherein R_Y is selected from C1-C6 alkyl; and R_Y is optionally substituted with one or more substituents P_1; the substituent P_1 is selected from R_W; R_W is selected from a 5-14 membered aryl or a 5-14 membered heteroaryl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; the substituent P_2 is selected from deuterium, tritium, hydroxyl, mercapto, cyano, oxo, thio, halogen, amino, carboxyl, sulfo-group or R_X; wherein R_X is selected from a C1-C6 alkyl, a C1-C6 alkoxy, or a C1-C6 alkyl thioether group;

R_{a2} is selected from hydrogen, deuterium, tritium, or a deuterated C1-C6 alkyl; or, R_{a2} is connected to R_{a1} (or R_{a3}) to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a is 0, 1 or 2.

12. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein X_b is  ; X_c is a chelating agent or  ; X_d is a chelating agent or  ; X_e is a chelating agent;

R_{a1}, R_{b1}, R_{c1} and R_{d1} are all R_{y1};

R_{a2}, R_{b2}, R_{c2} and R_{d2} are all R_{y2};

R_{a3}, R_{b3}, R_{c3} and R_{d3} are all R_{y3};

R_{y1} and R_{y3} are each independently selected from hydrogen, deuterium, tritium, R_Y, hydroxyl, mercapto, nitro, cyano, oxo, thio, halogen, amino, carboxyl, sulfo-group; R_Y is selected from a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl (including but not limited to: oxadiazolidinyl), a 5-14 membered aryl (including but not limited to: phenyl), or a 5-14 membered heteroaryl (including but not limited to: imidazolyl, oxadiazolyl, benzopyrrolyl);

R_Y is optionally substituted with one or more substituents P_1 or unsubstituted; the substituent P_1 is selected from deuterium, tritium, hydroxyl, mercapto, cyano, oxo, thio, halogen, $-NR_iR_j$, $-C(=O)R_k$, $-C(=O)OR_k$, $-S(=O)R_k$, $-S(=O)OR_k$, $-S(=O)(=O)R_k$, $-S(=O)(=O)OR_k$, $-C(=S)R_k$ or R_W;

R_W is selected from a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a C2-C6 alkenyl, a C2-C6 alkynyl, a 3-12 membered cycloalkyl, a 3-12 membered heterocyclic alkyl, a 5-14 membered aryl, or a 5-14 membered heteroaryl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; the substituent P_2 is selected from deuterium, tritium, hydroxyl, mercapto, cyano, oxo, thio, halogen, amino, carboxyl, sulfo-group or R_X; wherein R_X is selected from a C1-C6 alkyl, a C1-C6 alkoxy, or a C1-C6 alkyl thioether group;

R_k is selected from hydrogen, deuterium, tritium, $-NR_iR_j$, a C1-C6 alkyl, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, a halogenated C1-C6 alkyl, an amino-substituted C1-C6 alkyl, a carboxyl-substituted C1-C6 alkyl, or a sulfo-substituted C1-C6 alkyl;

R_i and R_j are each independently selected from hydrogen, deuterium, tritium, hydroxyl, mercapto, cyano, $-S(=O)R_z$, $-S(=O)OR_z$, $-S(=O)(=O)R_z$, $-S(=O)(=O)OR_z$, a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, a halogenated C1-C6 alkyl, an amino-substituted C1-C6 alkyl, a carboxyl-substituted C1-C6 alkyl, or a sulfo-substituted C1-C6 alkyl;

R_z is selected from hydrogen, deuterium, tritium, halogen, a C1-C6 alkyl, a deuterated C1-C6 alkyl, a tritiated C1-C6 alkyl, or a halogenated C1-C6 alkyl;

R_{y2} is selected from hydrogen, deuterium, tritium, a C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl; or, R_{y2} is connected to R_{y1} (or R_{y3}) to form $R_{ring\ A}$, the $R_{ring\ A}$ is a tetrahydropyrrole ring or a piperidine ring; the $R_{ring\ A}$ is optionally substituted with one or more substituents P_{1a} or unsubstituted; the substituent P_{1a} is selected from deuterium, tritium, halogen, hydroxyl, mercapto, nitro, cyano, amino, carboxyl, sulfo-group, a C1-C6 alkyl, a C1-C6 alkoxy, a C1-C6 alkyl thioether group, a halogenated C1-C6 alkyl, a deuterated C1-C6 alkyl, or a tritiated C1-C6 alkyl;

a, b, c and d are each independently selected from 0, 1 or 2.

13. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 12, wherein the compound of Formula I is:



Formula Ie

wherein X_c is a chelating agent;

or, the compound of Formula I is:



Formula If

wherein X_d is a chelating agent;

or, the compound of Formula I is:



Formula Ig

wherein X_e is a chelating agent.

or, the compound of Formula I is:



Formula Iy

wherein X_c is a chelating agent.

14. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 13, wherein the the compound of Formula Ie is selected from:



VWT023900 ,



VWT024200 ,



VWT037100 ,



VWT037200 ,



VWT038200 ,



VWT038400 ,



VWT039600 ,



VWT043300 ,



VWT044500 ,



VWT045900 ,



VWT046100 .

15. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein:

Q is  or  ; R_0 is selected from carbonyl or methylene;

X_b is a chelating agent or  ,  ; X_c is a chelating agent or  ,  ; X_d is a chelating agent or  ,  ; X_e is a chelating agent;

wherein R_{a1}, R_{b1}, R_{c1} and R_{d1}, R_{a2}, R_{b2}, R_{c2} and R_{d2}, R_{a3}, R_{b3}, R_{c3} and R_{d3}, a, b, c and d are as defined in claim 12.

16. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 15, wherein the compound of Formula I is:



Formula Ix

wherein X_b is  or , X_c is a chelating agent;

and/or,

R_{a1} and R_{b1} are each independently selected from hydrogen, deuterium, tritium or C1-C6 alkyl;

R_{a3} and R_{b3} are each independently selected from hydrogen, deuterium, tritium, carboxyl, sulfo-group or R_Y; wherein R_Y is a C1-C6 alkyl; and R_Y is optionally substituted with one or more substituents P_1 or unsubstituted; the substituent P_1 is selected from deuterium, tritium, hydroxyl, mercapto, halogen, carboxyl, sulfo-group or R_W; wherein R_W is selected from a C1-C6 alkoxy, a C1-C6 alkyl thioether group, phenyl, benzopyrrolyl or imidazolyl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; the substituent P_2 is selected from deuterium, tritium, hydroxyl, mercapto, halogen or a C1-C6 alkyl;

R_{a2} and R_{b2} are each independently selected from hydrogen, deuterium, tritium or a deuterated C1-C6 alkyl; or, R_{a2} is connected to R_{a1} to form $R_{ring\ A}$, R_{b2} is connected to R_{b1} to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a, b, c and d are each independently selected from 0, 1 or 2.

17. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 1, wherein the compound of Formula I is:



Formula Iw



wherein X_b is a chelating agent or , X_c is a chelating agent;

and/or,

R_{a1} and R_{b1} are each independently selected from hydrogen, deuterium, tritium or a C1-C6 alkyl;

R_{a3} and R_{b3} are each independently selected from hydrogen, deuterium, tritium, carboxyl, sulfo-group or R_Y; wherein R_Y is a C1-C6 alkyl; and R_Y is optionally substituted with one or more substituents P_1 or unsubstituted; the substituent P_1 is selected from deuterium, tritium, hydroxyl, mercapto, halogen, carboxyl, sulfo-group or R_W; wherein R_W is selected from a C1-C6 alkoxy, a C1-C6 alkyl thioether group, phenyl, benzopyrrolyl, or imidazolyl; and R_W is optionally substituted with one or more substituents P_2 or unsubstituted; the substituent P_2 is selected from deuterium, tritium, hydroxyl, mercapto, halogen or a C1-C6 alkyl;

R_{a2} and R_{b2} are each independently selected from hydrogen, deuterium, tritium or a deuterated C1-C6 alkyl; or, R_{a2} is connected to R_{a1} to form $R_{ring\ A}$, R_{b2} is connected to R_{b1} to form $R_{ring\ A}$, and the $R_{ring\ A}$ is a tetrahydropyrrole ring; and a, b, c and d are each independently selected from 0, 1 or 2.

18. The compound or pharmaceutically acceptable salt, ester or solvate thereof according to claim 17, wherein the compound of Formula Iw is selected from:



VWT049200 ,



VWT049400 ,



VWT0049900 ,



VWT050000 .

19. A radiolabeled complex comprising the compound or pharmaceutically acceptable salt, ester or solvate thereof according to any one of claims 1 to 18, and a radionuclide;

the radionuclide is selected from ^{94}Tc, ^{99m}Tc, ^{90}In, ^{111}In, ^{67}Ga, ^{68}Ga, ^{86}Y, ^{90}Y, ^{177}Lu, ^{151}Tb, ^{186}Re, ^{188}Re, ^{64}Cu, ^{67}Cu, ^{55}Co, ^{57}Co, ^{43}Sc, ^{44}Sc, ^{47}Sc, ^{225}Ac, ^{213}Bi, ^{212}Bi, ^{212}Pb, ^{227}Th, ^{153}Sm, ^{166}Ho, ^{152}Gd, ^{153}Gd, ^{157}Gd, ^{166}Dy, ^{55}Fe, ^{18}F, ^{11}C, ^{89}Zr, ^{123}I, ^{124}I, ^{125}I, ^{131}I or ^{211}At.

20. Use of the radiolabeled complex according to claim 19 in the preparation of a medicament for the diagnosis and/or treatment and/or prevention of tumors.